Reddit Traders Declare ‘BioWar’ as Shorted Biotechs Soar
(Bloomberg) -- BioCryst Pharmaceuticals Inc. blew past a five-year high as Reddit investors rallied around a call to start a “#BioWar” on the bears behind a heavily-shorted biotech that develops rare disease drugs.
The stock, which recently ended development of an experimental therapy for Covid-19, rallied to close 39% higher on Monday after a poster on Reddit's WallStreetBets forum called it “the most undervalued stock in the market” while another said a brewing #BioWar was “about sticking it to the shorts in a massive way.”
Biotechs with little to no revenue have long been the focus of short bets on Wall Street and could emerge as a new focal point for small-time investors railing against elite hedge funds. But the battleground is an already crowded arena with hedge funds positioned on both sides.
Read more: Citadel Silver Holding Exposes Rifts in WallStreetBets Army
Indeed, BioCryst is a short target with about 17% of float, or $259 million, sold short, according to financial analytics firm S3 Partners. But it's also a hedge fund pick held by the likes of Citadel, the well-known biotech outfit Baker Bros. Advisors LP, and activist investor Alex Denner's Sarissa Capital Management.
Before Monday's rally, shares of BioCryst had already shrugged off the scuttling of a Covid-19 trial supported by the National Institutes of Health. The company is expected to generate less than $31 million in revenue for all of 2020.
Novavax Inc., another heavily-shorted biotech, has also garnered interest across chat forums, which could benefit funds like RA Capital Management and Perceptive Advisors, which hold stakes in the company. The stock has more than doubled in the past few trading days, albeit on late-stage positive results for its Covid-19 vaccine candidate. The short position on Novavax stands at $1.5 billion, according to S3.
Read more: Carson Block Suspects Hedge Fund Coordination in Short Squeezes
Throughout the pandemic, biotechs racing to find the next Covid-19 treatment or vaccine have captured the imagination of retail investors. Dynavax Technologies Corp. added another $436 million in market value on Monday on news it had both initiated a mid-stage Covid vaccine study with one partner and that the U.K. had exercised an option to order more inoculations from another Dynavax partner using the company's adjuvant.
Inovio Pharmaceuticals Inc. also soared Monday after Twitter users jumped on a filing over BlackRock Inc.'s stake in the company. One tweet said BlackRock had doubled its position, although Bloomberg data show the stake is virtually unchanged.
Meanwhile, the motivations behind Monday's 131% rally in Healthier Choices Management Corp. powered by Reddit was unclear as Twitter users said it was an opportunity to send hedge funds “on the run.” Short interest in the sub-penny stock, which makes vaping products and operates health food stores in Florida, appears non-existent however. The micro-cap's largest holders were its management team.
©2021 Bloomberg L.P.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.